Chandan Krushna Das

@pgimer.edu.in

Associate Professor of Medical Oncology /Department of Clinical Hematology & Medical Oncology
Post Graduate Institute of Medical Education & Research, Chandigarh

Chandan Krushna Das


                  Download Compact PDF  
https://researchid.co/ckdasoncology
75

Scopus Publications

Scopus Publications

  • Phosphate Disorders in Cancer
    Joyita Bharati, Raad B. Chowdhury, Chandan Krushna Das, Hassan Izzedine, Kenar D. Jhaveri
    Kidney360, 2026
    Phosphate disorders are common in patients with cancer. Hypophosphatemia and hyperphosphatemia, both, can lead to significant morbidity, and their mechanisms are uniquely influenced by tumor biology, anti-cancer therapies, and cellular shifts. Malignancies that can influence phosphate include MM that can cause both hypo- and hyperphosphatemia. Tumor-induced osteomalacia can lead to hypophosphatemia as well. Drug-induced renal phosphate wasting is a contributor to hypophosphatemia often associated with platinum-based therapy and tyrosine kinase inhibitors. Conversely, hyperphosphatemia often results from tumor lysis syndrome and can manifest as symptomatic hypocalcemia and acute kidney injury. A step wise approach in determining the mechanism of hypophosphatemia and hyperphosphatemia is crucial to identify most appropriate treatment, especially with the expanding use of novel cancer therapies. This review summarizes the key mechanisms and management of phosphate disorders in oncology care in the current era.
  • Novel framework for response evaluation criteria in grade 1/2 neuroendocrine tumors (RECIN) following [177Lu]Lu-DOTATATE therapy: post-hoc analysis of the phase 2 LuCAP trial
    Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, Kunal R Chandekar, Chandan K Das, Rajesh Gupta, Divya Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, Bhagwant R Mittal
    European Journal of Nuclear Medicine and Molecular Imaging, 2025
  • 177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer: A Randomized, Phase 2 Trial
    Swayamjeet Satapathy, Chandan K. Das, Shikha Goyal, Ashwani Sood, Kannan Periasamy, Piyush Aggarwal, Komal Preet, Shrawan K. Singh, Ravimohan S. Mavuduru, Girdhar S. Bora, Aditya P. Sharma, Gaurav Prakash, Rajender Kumar, Harmandeep Singh, Bhagwant R. Mittal
    Journal of Nuclear Medicine, 2025
    Visual Abstract 177Lu-prostate-specific membrane antigen-617 (177Lu-PSMA-617) has shown positive survival outcomes in metastatic castration-resistant prostate cancer. However, there are limited data in the hormone-sensitive setting. Here, in the CONSOLIDATE trial (177Lu-PSMA-617 Consolidation Therapy After Docetaxel in Patients with Synchronous High-Volume Metastatic Hormone-Sensitive Prostate Cancer), we intended to evaluate the role of 177Lu-PSMA-617 as consolidation therapy for residual disease after chemohormonal treatment in patients with synchronous high-volume metastatic hormone-sensitive prostate cancer (mHSPC). Methods: This was an investigator-initiated randomized, parallel-group, open-label phase 2 trial. Synchronous high-volume mHSPC patients treated with androgen-deprivation therapy plus docetaxel and having residual nonprogressive disease after docetaxel completion (defined as prostate-specific antigen [PSA] > 0.2 ng/mL with PSMA-positive disease on 68Ga-PSMA-11 PET/CT) were randomized in a 1:1 ratio to the experimental arm (177Lu-PSMA-617, 7.4 GBq/cycle × 2, 6 wk apart with protocol-permitted standard of care) or control arm (protocol-permitted standard of care alone). The primary endpoint was the proportion of patients achieving a PSA level of 0.2 ng/mL or less at 6 mo from randomization. Secondary endpoints included objective radiographic response rate, radiographic progression-free survival (PFS), PSA PFS, and toxicities. Results: The trial was terminated early because of poor accrual after the coronavirus disease pandemic and a change in treatment guidelines for mHSPC. Thirty high-volume mHSPC patients were randomized between January 2021 and June 2024. The primary endpoint was achieved in 9 of 15 (60%; 95% CI, 35%–85%) patients in the experimental arm versus 2 of 15 (13%; 95% CI, 0%–30%) in the control arm (risk ratio, 4.5; 95% CI, 1.2–17.4; P = 0.008). The objective radiographic response rates were 8 of 15 (53%; 95% CI, 28%–78%) and 1 of 15 (7%; 95% CI, 0%–19%) in the experimental and control arms, respectively (P = 0.014). The estimated median radiographic PFS and PSA PFS were 18 mo (95% CI, 9–27 mo) and 15 mo (95% CI, 12–18 mo), respectively, in the experimental arm versus 9 mo (95% CI, 4–14 mo) and 9 mo (95% CI, 1–17 mo), respectively, in the control arm. No grade 3 or 4 toxicity was noted with the addition of 177Lu-PSMA-617 in the experimental arm. Conclusion: In synchronous high-volume mHSPC patients having residual disease after chemohormonal treatment, 177Lu-PSMA-617 consolidation therapy demonstrated promising efficacy and safety outcomes. Larger phase 3 trials are warranted to definitively establish its survival benefit.
  • 177Lu-DOTATATE Plus Capecitabine Versus 177Lu-DOTATATE Alone in Patients with Advanced Grade 1/2 Gastroenteropancreatic Neuroendocrine Tumors (LuCAP): A Randomized, Phase 2 Trial
    Swayamjeet Satapathy, Piyush Aggarwal, Ashwani Sood, Kunal R. Chandekar, Chandan K. Das, Rajesh Gupta, Divya Khosla, Namrata Das, Rakesh Kapoor, Rajender Kumar, Harmandeep Singh, Jaya Shukla, Ajay Kumar, Bhagwant Rai Mittal
    Journal of Nuclear Medicine, 2025
    177Lu-DOTATATE has emerged as a viable treatment strategy for advanced well-differentiated grade 1/2 gastroenteropancreatic neuroendocrine tumors (GEP-NETs). Few retrospective studies have shown concomitant 177Lu-DOTATATE with radiosensitizing low-dose capecitabine to be effective in advanced NETs. However, this has not been validated in prospective randomized-controlled trials. Methods: In this investigator-initiated, parallel-group, open-label, phase 2 trial, patients with grade 1/2 GEP-NETs, having progressive somatostatin receptor-positive, locally advanced, or metastatic disease on 68Ga-DOTANOC PET/CT, were randomly assigned in a 1:1 ratio to 177Lu-DOTATATE plus capecitabine (experimental arm) or 177Lu-DOTATATE only (control arm). 177Lu-DOTATATE was administered at approximately 7.4 GBq/cycle intravenously, for up to 4 cycles, at 8 wk intervals, whereas capecitabine was given at 1,250 mg/m2/d orally from day 0 to day 14 of each cycle of 177Lu-DOTATATE. The primary endpoint was the objective response rate. Secondary endpoints included the disease control rate, progression-free survival, overall survival, and adverse events. Results: Seventy-two patients (median age, 53 y; range, 18-79 y) were enrolled. The objective response rate was 33.3% (95% CI, 18.6-50.9%) in the experimental arm versus 30.6% (95% CI, 16.4-48.1%) in the control arm (P = 0.800). The disease control rate was 88.9% (95% CI, 73.9-96.9%) and 91.7% (95% CI, 77.5-98.2%) in the experimental and control arms, respectively (P = 1.000). The estimated median progression-free survival in the experimental arm was 29 mo (95% CI, 22-29 mo) versus 31 mo (95% CI, 29-32 mo) in the control arm (P = 0.401). The median overall survival was not reached in either arm (P = 0.876). Overall, adverse events of at least grade 3 were noted in 7 patients in the experimental arm versus 6 patients in the control arm (P = 0.759). Conclusion: Based on the results of this trial, the addition of low-dose capecitabine to 177Lu-DOTATATE in advanced grade 1/2 GEP-NETs did not lead to superior radiographic responses. Further studies are needed to evaluate its potential role in high-grade NETs.
  • Aflatoxin exposure is associated with an increased risk of gallbladder cancer
    Amit Yadav, Pankaj Gupta, Parikshaa Gupta, Amol N. Patil, Chandan K. Das, Harish Hooda, Deepa Thakur, Vishal Sharma, Anupam K. Singh, Thakur Deen Yadav, Lileswar Kaman, Jarnail Singh Thakur, Hari Kishan Sudini, Radhika Srinivasan, Usha Dutta
    International Journal of Cancer, 2025
    Gall bladder cancer (GBC) is common among the socioeconomically deprived populations of certain geographical regions. Aflatoxin is a genotoxic hepatocarcinogen, which is recognized to have a role in the pathogenesis of hepatocellular carcinoma. However, the role of aflatoxin in the pathogenesis of GBC is largely unknown. We determined serum AFB1‐Lys albumin adduct (AAA) levels as a marker of aflatoxin exposure in the patients with GBC and compared to those without GBC. The relationship of AAA levels to cytogenetic (TP53mutation&HER2/neu amplification) and radiological characteristics of the tumor was assessed. We included GBC cases (n = 51) and non‐GBC controls (n = 100). Mean serum AAA levels were higher in the GBC group (n = 51) than those without GBC (n = 100) (26.1 ± 12.2 vs. 13.1 ± 11.9 ng/mL; p < .001). HER2/neu expression was associated with higher AAA levels compared to those with equivocal or negative expression (43.9 ± 3 vs. 28.6 ± 10 vs. 19.3 ± 7 ng/mL; p < .001). Older age (age >50 years) (odds ratio [OR] = 3.2 [CI: 1.3–8.2]; p = .013), positive Helicobacter pylori serology (OR = 5.1 [CI: 1.4–17.8]; p = .012), presence of GS (OR = 5 [CI: 1.5–16.9]; p = .009) and detectable AAA levels (OR = 6.8 [CI: 1.3–35.7]; p = .024) were independent risk factors for the presence of the GBC among all study subjects. Among patients harboring GS, older age (age >50 years) (OR = 4.5 [CI: 1.3–14.9]; p = .015), female gender (OR = 3.8 [CI: 1.2–12.5]; p = .027), presence of multiple GS (OR = 21.9 [CI: 4.8–100.4]; p < .001) and high serum AAA levels (OR = 5.3 [CI: 1.6–17.3]; p = .006) were independent risk factors for the presence of the GBC. Elderly age >50 years (OR = 2.6 [CI: 1.3–5.2]; p = .010) and frequent peanut consumption (OR = 2.3 [CI: 1.1–4.9]; p = .030) were independent risk factors for high serum AAA levels. The current study has implications for the prevention of GBC through the reduction of dietary aflatoxin exposure.
  • Darolutamide in Combination with Androgen-Deprivation Therapy in Patients with Metastatic Hormone-Sensitive Prostate Cancer from the Phase III ARANOTE Trial
    Fred Saad, Egils Vjaters, Neal Shore, David Olmos, Nianzeng Xing, Andrea Juliana Pereira de Santana Gomes, Augusto Cesar de Andrade Mota, Pamela Salman, Mindaugas Jievaltas, Albertas Ulys, Maris Jakubovskis, Evgeny Kopyltsov, Weiqing Han, Liina Nevalaita, Isabella Testa, Marie-Aude Le Berre, Iris Kuss, Kunhi Parambath Haresh, Vinod Ganju, Howard Gurney, Laurence Krieger, Vineet Kwatra, Sanjeev Sewak, Amanda Stevanovic, Andrew Weickhardt, Alan Azambuja, Flavio Mavignier Carcano, Marcio Valerio Costa, Felipe Cruz, Juliana de Menezes, Charles Andree Joseph de Padua, Adriano Augusto de Paula, Carlos Eugenio Santiago Escovar, Fabio Leite Couto Fernandez, Otavio Gampel, Andrea Juliana P. de Santana Gomes, Murilo Luz, Gisele Marinho dos Santos, Augusto Cesar de Andrade Mota, Lucas Nogueira, Daniel D'Almeida Preto, Alexandre Sant'Anna, Katsuki Aruma Tiscoski, Jonathan Giddens, Godfrey Jansz, Julian Kim, Paul Quellette, Fred Saad, George Vrabec, Alejandro Acevedo Gaete, Christian Caglevic Medina, Javier Dominguez Cruzat, Marcelo Garrido Salvo, Pedro Octavio Pastor Arroyo, Anibal Salazar Huerta, Pamela Salman Boghikian, Yasna Daniela Valenzuela Velasquez, Ariel Zwenger, Cheng Fu, Hongqian Guo, Weiqing Han, Haowen Jiang, Junhui Jiang, Shusuan Jiang, Lei Li, Tongzu Liu, Zhenhua Liu, Lulin Ma, Jun Qi, Mingxing Qiu, Guowei Shi, Ye Tian, Ben Wan, Chun-Xi Wang, Dongwen Wang, Shaogang Wang, Xiaolin Wang, Shaozhong Wei, Jitao Wu, Jun Xiao, Keji Xie, Liping Xie, Nianzeng Xing, Boxin Xue, Zejun Yan, Yong Yang, Zhixian Yu, Dahong Zhang, Song Zheng, Fangjian Zhou, Suresh Advani, Pawan Agarwal, Niraj Bhatt, Dubashi Biswajit, Ghanashyam Biswas, Shailesh A. Bondarde, Chandan Das, SarojKumar Das Majumdar, Sujoy Gupta, Kunhi Parambath Haresh, Francis James, Pamela Jeyaraj, Amit Joshi, Suman Kalyan, Bhalchandra Kashyapi, Ashish Kaushal, Raghunath Krishnappa, Ravimohan Mavuduru, Rajanish Nagarkar, Harsha Panchal, Gourav Parkash, Ashwin Philips, Ginil Kumar Pooleri, Vikram Prabha, Krishna Kumar Rathnam, Naveen Ravel, Sudhir Rawal, Boya Rakesh Reddy, Manasi Shah, Praveena Voonna, Andrejs Aleksandrovs, Maris Jakubovskis, Alvis Laukmanis, Vilnis Lietuvietis, Mareks Vejins, Egils Vjaters, Mindaugas Jievaltas, Albertas Ulys, Raimundas Venckus, Arunas Zelvys, Kevin Bax, Peter Gilling, Michael Holmes, Alvin Tan, Carlos Manuel Morante Deza, Alberto Juan Pazos Franco, Jorge Fernando Salas Sanchez, Alejandro Figueroa Torrejon, Timur Andabekov, Vagif Atduev, Yana Chapko, Natalya Fadeeva, Alexander Filippov, Rustem Gafanov, Oleg Gladkov, Boris Kasparov, Denis Kholtobin, Evgeny Kopyltsov, Alexander Lykov, Marina Nechaeva, Alexey Plekhanov, Sufia Safina, Andrey Semenov, Mikhail Shkolnik, Pavel Skopin, Roman Smirnov, Ekaterina Solovyeva, Alexander Sultanbaev, Mikhail Zavyalov, Alexandr Zyryanov, Khabane Chabane, Corlia Coetzee, Conrad Jacobs, Thamsanqa Madlala, Jorn Malan, Sophie Mathijs, Carlos Llorente Abarca, Daniel Ernesto Castellano Gauna, Jose Luis Alvarez-Ossorio Fernandez, Enrique Gallardo Diaz, Pablo Borrega Garcia, Bernardo Herrera Imbroda, Rafael Antonio Medina Lopez, Josep Maria Gaya Sopena, Hsiao-Jen Chung, Shu-Pin Huang, Yuh-Shya Tsai, Pai-Fu Wang, Shian-Shiang Wang, Igor Bondarenko, Yurii Golovko, Petro Ivashchenko, Viktor Paramonov
    Journal of Clinical Oncology, 2024
    PURPOSE For patients with metastatic hormone-sensitive prostate cancer (mHSPC), delaying progression to castration-resistant disease is important not only for overall survival (OS) but also for patients' quality of life. Darolutamide plus androgen-deprivation therapy (ADT) with docetaxel improved OS versus ADT and docetaxel in patients with mHSPC. The ARANOTE trial evaluated darolutamide and ADT without chemotherapy in patients with mHSPC. METHODS In this global phase III trial, patients were randomly assigned 2:1 to receive darolutamide 600 mg twice daily or placebo, with concomitant ADT. The primary end point was radiological progression-free survival (rPFS). RESULTS From March 2021 to August 2022, 669 patients were randomly assigned (darolutamide n = 446; placebo n = 223). At the primary cutoff date (June 7, 2024), darolutamide plus ADT significantly improved rPFS, reducing the risk of radiological progression or death by 46% versus placebo plus ADT (hazard ratio [HR], 0.54 [95% CI, 0.41 to 0.71]; P < .0001), with consistent benefits across subgroups, including high- and low-volume disease. OS results were suggestive of benefit with darolutamide versus placebo (HR, 0.81 [95% CI, 0.59 to 1.12]), and clinical benefits were seen across all other secondary end points, including delayed time to metastatic castration-resistant prostate cancer (HR, 0.40 [95% CI, 0.32 to 0.51]) and time to pain progression (HR, 0.72 [95% CI, 0.54 to 0.96]). Adverse events were similar in the two groups. Notably, the incidence of fatigue was lower in patients receiving darolutamide (5.6%) versus those receiving placebo (8.1%), and fewer patients receiving darolutamide (6.1%) versus placebo (9.0%) discontinued treatment because of adverse events. CONCLUSION These results confirm the efficacy and tolerability of darolutamide plus ADT in patients with mHSPC, demonstrating clinically and statistically significant improvement in rPFS and a favorable safety profile consistent with prior phase III darolutamide trials.
  • Primary renal leiomyosarcoma in adult patients: a systematic review and individual patient data analysis
    Kannan Periasamy, Treshita Dey, Shikha Goyal, Renu Madan, Santosh Kumar, Sudheer Kumar Devana, Thiraviyam Elumalai, Prashanth Giridhar, Sushmita Ghoshal, Rakesh Kapoor, Chandan K. Das
    African Journal of Urology, 2024
    Purpose The optimal management of primary renal leiomyosarcomas is unknown owing to its rarity and minimal available information about their primary, adjuvant treatment and clinical outcomes. This study systematically reviews treatment evidence and effects in terms of survival for leiomyosarcomas arising primarily from kidney, renal pelvis and renal vessels. Method PubMed and Embase databases were searched from inception to March 2023, with manual searches of reference lists. Two investigators independently reviewed the studies reporting management and survival outcomes of renal leiomyosarcomas. Results A total of 85 publications met inclusion criteria, reporting on 188 cases. The median age was 55.5 years, predominantly female [52.7%]. Pain was the most common presenting symptom [41.5%], and most tumors were high grade [45.8%]. Complete surgical resection with negative margins forms definitive treatment. The median disease-free survival and overall survival (OS) for all reviewed patients were 24 months [95%CI 4.1–43.9] and 42 months [95%CI 32.5–51.4], respectively. The OS of 1 year, 2 year, 3 year and 5 year was 78.8%, 64.4%, 53.8% and 38.9%, respectively. On univariate analysis, favorable factors for OS included tumor size ≤ 5 cm, low-grade histology, tumors of renal vascular origin and non-metastatic disease at presentation. Neoadjuvant or adjuvant treatment with either radiotherapy or chemotherapy has been shown to improve OS (NR vs. 36 months, p < 0.001), especially for high-grade tumors > 5 cm in size. Conclusion Radical nephrectomy with en bloc tumor resection with negative margins forms the mainstay of treatment for renal leiomyosarcomas. Adjuvant radiotherapy or chemotherapy appears to improve OS. To validate this treatment strategy, prospective multicentric efforts are required to acquire reliable data from randomized trials.
  • Neuroendocrine tumor of the liver in pregnancy: A very rare case report
    Ramya Lasmi, Ramandeep Bansal, Vanita Suri, Chandan Krushna Das, Reetu Kundu
    International Journal of Gynecology and Obstetrics, 2024
    Neuroendocrine neoplasms (NENs) of the liver represent a rare entity. Amongst this group of uncommon diseases primary hepatic neuroendocrine neoplasm (PH‐NEN) represent only 0.3% of all NENs. Moreover, PH‐NEN has very rarely been reported in pregnancy. We report a 28‐year‐old young patient with metastatic small cell neuroendocrine carcinoma of the liver complicated with pregnancy. She was evaluated and managed through a multidisciplinary team approach and received two cycles of chemotherapy with a cisplatin/etoposide regimen during the antenatal period and delivered at 37 weeks period of gestation (POG). This case highlights the importance of major challenges faced during the diagnosis and management of this very rare disease in pregnancy and the successful fetomaternal outcome.
  • From foes to friends: rethinking the role of lymph nodes in prostate cancer
    Raghav Gupta, Chandan K. Das, Sujit S. Nair, Adriana Marcela Pedraza-Bermeo, Ali H. Zahalka, Natasha Kyprianou, Nina Bhardwaj, Ashutosh K. Tewari
    Nature Reviews Urology, 2024
  • Efficacy and Safety of Biosimilar Cetuximab Versus Innovator Cetuximab in Indian Patients With Head and Neck Cancer: A Multicenter, Randomized, Double-Blind, Phase III Trial
    Kumar Prabhash, Chetan Deshmukh, Hemant Malhotra, Atul Sharma, Minish Jain, Nilesh Dhamne, Rajnish Nagarakar, Prasantha Ganesan, Vijay K. Mahobia, Chandan K. Das, Rejnish Kumar, Prakash S. Shivanna, Manu P. Avaronnan, Puligundla K. Chaithanya, Vaibhav Chaudhary, Kartar Singh, Suhas Aagre, Bellala Ravishankar, Dhruv Mehta, Kandipalli Shilpa, Vashishth Maniar, Koushik Chatterjee, Saroj D. Majumdar, Rohitashwa Dana, Vanita Noronha, Nandini Menon, Akhilesh Sharma, Roshan Pawar, Vinayaka Shahavi, Rajiv Yadav, Amol Aiwale
    JCO Global Oncology, 2024
    PURPOSE Squamous cell carcinoma of the head and neck (SCCHN) is the sixth most common cancer, with approximately 225,419 new cases with over 125,000 deaths annually in India. This trial compared the efficacy and safety of biosimilar cetuximab versus innovator cetuximab (IC) in combination with platinum-based chemotherapy in patients with recurrent locoregional or metastatic SCCHN. METHODS This phase III trial is a multicenter, randomized, double-blind and parallel group study performed in Indian patients with recurrent locoregional or metastatic SCCHN. Patients were randomly assigned in 2:1 ratio to receive biosimilar cetuximab and IC in combination with cisplatin and fluorouracil via intravenous infusions. The primary end points were disease control rate (DCR) and overall response rate (ORR) as per response evaluation criteria in solid tumors version 1.1. The secondary end points included pharmacokinetics (PK), immunogenicity, safety, and tolerability. RESULTS Of 180 patients enrolled, 120 patients received biosimilar cetuximab and 60 patients received IC treatment. No significant statistical difference was observed in the primary outcomes between two groups. Treatment difference in DCR and ORR response was found to be –5.21 (90% CI, –8.94 to –1.48) and –4.79 (90% CI, –19.42 to 9.84), respectively, indicating noninferiority to reference product. The incidence of treatment-emergent adverse events (AEs; biosimilar cetuximab: 89.2% v IC: 91.7%; P = .8364) and serious AEs (biosimilar cetuximab: 23.3% v IC: 13.3%; P = .0603) and PK parameters were comparable between treatment groups. The immunogenicity findings showed higher incidence of anticetuximab antibodies in the biosimilar cetuximab group compared with the IC group at the end of Study. CONCLUSION The findings of this study demonstrated noninferiority along with comparable PK, safety, and immunogenicity of biosimilar cetuximab and IC in patients with recurrent or metastatic SCCHN.
  • Contrast Enhanced CT Versus MRI for Accurate Diagnosis of Wall-thickening Type Gallbladder Cancer
    Daneshwari Kalage, Pankaj Gupta, Ajay Gulati, Kakivaya P. Reddy, Kritika Sharma, Ati Thakur, Thakur D. Yadav, Vikas Gupta, Lileswar Kaman, Ritambhra Nada, Harjeet Singh, Santosh Irrinki, Parikshaa Gupta, Chandan K. Das, Usha Dutta, Manavjit Sandhu
    Journal of Clinical and Experimental Hepatology, 2024
  • Early response assessment to targeted therapy in metastatic clear cell renal cancer using 68Ga-PSMA-11 PET/CT and comparison with CECT: a feasibility study
    Piyush Aggarwal, Harmandeep Singh, Chandan K. Das, Ravimohan S. Mavuduru, Anupam Lal, Nandita Kakkar, Rajender Kumar, Ujjwal Gorsi, Pratibha Prashar, Bhagwant R. Mittal
    Clinical and Translational Imaging, 2024
  • Safety and Efficacy of177Lu-DOTATATE in Children and Young Adult Population: A Single-Center Experience
    Piyush Aggarwal, Swayamjeet Satapathy, Ashwani Sood, Harmandeep Singh, Bhagwant Rai Mittal, Sadhna Lal, Rajesh Gupta, Chandan Krushna Das, Thakur Deen Yadav, Rama Walia
    Clinical Nuclear Medicine, 2024
  • Agreement of Gallbladder Reporting and Data System for Gallbladder Wall Thickening at Ultrasonography: A Multireader Validation Study
    Raghuraman Soundararajan, Pavithra Subramanian, Pankaj Gupta, Pratyaksha Rana, Manika Chhabra, Shravya Singh, Ruby Siddiqui, Chandan Das, Thakur D. Yadav, Vikas Gupta, Lileswar Kaman, Harjeet Singh, Santosh Irrinki, Parikshaa Gupta, Uma N. Saikia, Ritambhra Nada, Usha Dutta, Manavjit S. Sandhu
    Journal of Clinical and Experimental Hepatology, 2024
  • Deep-learning enabled ultrasound based detection of gallbladder cancer in northern India: a prospective diagnostic study
    Pankaj Gupta, Soumen Basu, Pratyaksha Rana, Usha Dutta, Raghuraman Soundararajan, Daneshwari Kalage, Manika Chhabra, Shravya Singh, Thakur Deen Yadav, Vikas Gupta, Lileswar Kaman, Chandan Krushna Das, Parikshaa Gupta, Uma Nahar Saikia, Radhika Srinivasan, Manavjit Singh Sandhu, Chetan Arora
    Lancet Regional Health Southeast Asia, 2024
  • Validation of a Zero-shot Learning Natural Language Processing Tool to Facilitate Data Abstraction for Urologic Research
    Basil Kaufmann, Dallin Busby, Chandan Krushna Das, Neeraja Tillu, Mani Menon, Ashutosh K. Tewari, Michael A. Gorin
    European Urology Focus, 2024
  • Proposal for a new morphological “combined type” of gallbladder cancer: description of radiopathological characteristics and comparison with other morphological types
    Manika Chhabra, Daneshwari Kalage, Pankaj Gupta, Ruby Siddiqui, Shravya Singh, Thakur Deen Yadav, Vikas Gupta, Lileswar Kaman, Harjeet Singh, Santosh Irrinki, Chandan Das, Gaurav Prakash, Parikshaa Gupta, Uma Nahar Saikia, Ritambhra Nada, Usha Dutta, Manavjit Singh Sandhu
    Abdominal Radiology, 2024
  • Sunitinib in Tandem With 177Lu-DOTATATE Therapy in Advanced Pancreatic Neuroendocrine Tumor A New Treatment Approach
    Piyush Aggarwal, Vinisha Gunasekaran, Ashwani Sood, Kushal Gupta, Chandan Krushna Das, Bhagwant Rai Mittal
    Clinical Nuclear Medicine, 2024
  • Intraoperative Fluorescent Image Guidance for Nerve-Sparing Prostatectomy: A Review of Historical Context and Current Research
    Asher Mandel, Chandan Das, Richard Ting, Basil Kaufmann, Ashutosh Tewari
    Journal of Endourology, 2024
  • Potential role of 68Ga-PSMA PET/CT in metastatic renal cell cancer: A prospective study
    Piyush Aggarwal, Harmandeep Singh, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Nandita Kakkar, Anupam Lal, Ujjwal Gorsi, Rajender Kumar, Bhagwant Rai Mittal
    European Journal of Radiology, 2024
  • Memory B cells predict outcome in primary podocytopathies of adults
    Joyita Bharati, Jhumki Das, Pandiarajan Vignesh, Kenar D Jhaveri, Arun Prabhahar, Chandan Krushna Das, Anita Singh Parihar, Ritambhra Nada, Raja Ramachandran, Amit Rawat, Harbir Singh Kohli
    Nephrology Dialysis Transplantation, 2023
  • [177Lu]Lu-PSMA-617 Versus Docetaxel in Chemotherapy-Naïve Metastatic Castration-Resistant Prostate Cancer: Final Survival Analysis of a Phase 2 Randomized, Controlled Trial
    Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Shikha Goyal, Jaya Shukla, Shrawan Kumar Singh
    Journal of Nuclear Medicine, 2023
  • Kidney and urinary tract involvement in systemic mastocytosis
    Joyita Bharati, Nikita Shah, Ankuri Desai, Douglas Gladstone, Chandan Krushna Das, Maria Jacqueline Nieto, Kenar D Jhaveri, Hassan Izzedine
    Nephrology Dialysis Transplantation, 2023
  • Sonographic “Cervix Sign”: A New Ancillary Sign of Gallbladder Neck Malignancy
    Pratyaksha Rana, Himanshu Pruthi, Pankaj Gupta, Manika Chhabra, Raghuraman Soundararajan, Shravya Singh, Ajay Gulati, Chandan K. Das, Thakur D. Yadav, Vikas Gupta, Parikshaa Gupta, Uma N. Saikia, Usha Dutta, Manavjit Sandhu
    Journal of Clinical and Experimental Hepatology, 2023
  • An audit of the adequacy of first-time ultrasound reports in patients with non-acute gallbladder wall thickening: Need for gallbladder reporting and data system
    Maninder Kaur, Pankaj Gupta, Sreenivasulu D, Pratyaksha Rana, Raghuraman Soundararajan, Daneshwari Kalage, Chandan K Das, Thakur Deen Yadav, Vikas Gupta, Lileswar Kaman, Parikshaa Gupta, Uma Nahar Saikia, Usha Dutta
    Indian Journal of Gastroenterology, 2023
  • Gastrointestinal involvement in gallbladder cancer: Computed tomography findings and proposal of a classification system
    Raghuraman Soundararajan, Srivardhan Vanka, Pankaj Gupta, Manika Chhabra, Pratyaksha Rana, Ajay Gulati, Chandan K. Das, Parikshaa Gupta, Uma Nahar Saikia, Thakur Deen Yadav, Vikas Gupta, Lileswar Kaman, Harjeet Singh, Santosh Irrinki, Usha Dutta, Manavjit Singh Sandhu
    Indian Journal of Gastroenterology, 2023
  • Multiparametric MR imaging with diffusion-weighted, intravoxel incoherent motion, diffusion tensor, and dynamic contrast-enhanced perfusion sequences to assess gallbladder wall thickening: a prospective study based on surgical histopathology
    Daneshwari Kalage, Pankaj Gupta, Ajay Gulati, Thakur Deen Yadav, Vikas Gupta, Lileswar Kaman, Ritambhra Nada, Harjeet Singh, Santosh Irrinki, Parikshaa Gupta, Chandan Das, Usha Dutta, Manavjit Sandhu
    European Radiology, 2023
  • Association of CT Findings With Perineural Invasion in Gallbladder Cancer: Preliminary Assessment
    Yashi Marodia, Jyoti Kharel, Uma N. Saikia, Rajender Kumar, Thakur D. Yadav, Vikas Gupta, Lileshwar Kaman, Chandan K. Das, Usha Dutta, Pankaj Gupta
    American Journal of Roentgenology, 2023
  • Long-term real-world outcomes of patients with acute promyelocytic leukaemia treated with arsenic trioxide and all-trans retinoic acid without chemotherapy—a retrospective, single-centre study
    Charanpreet Singh, Uday Yanamandra, Parathan Karunakaran, Nishant Jindal, Saloni Rani Kumar, Neha Saini, Aditya Jandial, Arihant Jain, Chandan Das, Deepesh Lad, Gaurav Prakash, Alka Khadwal, Shano Naseem, Reena Das, Neelam Varma, Subhash Varma, Pankaj Malhotra
    British Journal of Haematology, 2023
  • Genomic characterization of metastatic castration-resistant prostate cancer patients undergoing PSMA radioligand therapy: A single-center experience
    Swayamjeet Satapathy, Chandan K. Das, Piyush Aggarwal, Ashwani Sood, Ashwin S. Parihar, Shrawan K. Singh, Bhagwant R. Mittal
    Prostate, 2023
  • Randomized crossover trial of ‘Roll-over’ technique of abdominal paracentesis versus standard technique in suspected malignant ascites
    Daya Krishna Jha, Manish Rohilla, Chandan K Das, Santhosh Irrinki, Harjeet Singh, Aashima Arora, Subhas C Saha, Pankaj Gupta, Harshal S Mandavdhare, Usha Dutta, Aman Sharma, Vishal Sharma
    Expert Review of Gastroenterology and Hepatology, 2023
  • Short Research Communication Anti-Spike Antibody Response to COVISHIELD™ (SII-ChAdOx1 nCoV-19) Vaccine in Patients with B-Cell and Plasma Cell Malignancies and Hematopoietic Cell Transplantation Recipients
    Madhu Chopra, Arihant Jain, Sanjeev Chhabra, Shaweta Kaundal, Charanpreet Singh, Aditya Jandial, Gaurav Prakash, Alka Khadwal, Chandan Das, Mini P Singh, Reena Das, Pankaj Malhotra, Deepesh P. Lad
    Indian Journal of Hematology and Blood Transfusion, 2022
  • Nivolumab Immunotherapy-Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer
    Thayumanavan T, Harish Goyal, Harmandeep Singh, Chandan K. Das, Aravind Sekar, Rajender Kumar
    Clinical Nuclear Medicine, 2022
  • 177Lu-PSMA-617 versus docetaxel in chemotherapy-naïve metastatic castration-resistant prostate cancer: a randomized, controlled, phase 2 non-inferiority trial
    Swayamjeet Satapathy, Bhagwant Rai Mittal, Ashwani Sood, Chandan Krushna Das, Ravimohan Suryanarayan Mavuduru, Shikha Goyal, Jaya Shukla, Shrawan Kumar Singh
    European Journal of Nuclear Medicine and Molecular Imaging, 2022
  • Alpha Before Beta: Exceptional Response to First-Line 225Ac-DOTATATE in a Patient of Metastatic Neuroendocrine Tumor With Extensive Skeletal Involvement
    Swayamjeet Satapathy, Ashwani Sood, Chandan Krushna Das, Anwin Joseph Kavanal, Bhagwant Rai Mittal
    Clinical Nuclear Medicine, 2022
  • Gallbladder reporting and data system (GB-RADS) for risk stratification of gallbladder wall thickening on ultrasonography: an international expert consensus
    Pankaj Gupta, Usha Dutta, Pratyaksha Rana, Manphool Singhal, Ajay Gulati, Naveen Kalra, Raghuraman Soundararajan, Daneshwari Kalage, Manika Chhabra, Vishal Sharma, Vikas Gupta, Thakur Deen Yadav, Lileshwar Kaman, Santosh Irrinki, Harjeet Singh, Yashwant Sakaray, Chandan Krishuna Das, Uma Saikia, Ritambhara Nada, Radhika Srinivasan, Manavjit Singh Sandhu, Raju Sharma, Nitin Shetty, Anu Eapen, Harmeet Kaur, Avinash Kambadakone, Robbert de Haas, Vinay K. Kapoor, Savio George Barreto, Atul K. Sharma, Amol Patel, Pramod Garg, Sujoy K. Pal, Mahesh Goel, Shraddha Patkar, Anu Behari, Anil K. Agarwal, Bhawna Sirohi, Milind Javle, Giuseppe Garcea, Flavio Nervi, Volkan Adsay, Juan Carlos Roa, Ho-Seong Han
    Abdominal Radiology, 2022
  • Immune Checkpoint Inhibitors in Cancer Therapy: A Ray of Hope
    Chandan Krushna Das, Shrawan K. Singh
    Biomedical Translational Research from Disease Diagnosis to Treatment, 2022
  • Chronic Myeloid Leukemia Blast Crisis: An Emergency
    Gaurav Prakash, Urmimala Bhattacharjee, Chandan K. Das
    Onco Critical Care an Evidence Based Approach, 2022
  • Stereotactic body radiation therapy for metastatic urethral melanoma in a male patient
    Journal of Radiosurgery and Sbrt, 2022
  • High-dose hydroxyurea with differentiating agents for treating ultra-high-risk acute promyelocytic leukemia in resource-challenged settings
    Charanpreet Singh, Sarthak Wadhera, Uday Yanamandra, Parathan Karunakaran, Nishant Jindal, Saloni Rani Kumar, Neha Saini, Aditya Jandial, Arihant Jain, Chandan Das, Gaurav Prakash, Alka Khadwal, Shano Naseem, Reena Das, Neelam Varma, Subhash Varma, Pankaj Malhotra, Deepesh Lad
    Acta Oncologica, 2022
  • Evolving role of 225Ac-PSMA radioligand therapy in metastatic castration-resistant prostate cancer—a systematic review and meta-analysis
    Swayamjeet Satapathy, Ashwani Sood, Chandan Krushna Das, Bhagwant Rai Mittal
    Prostate Cancer and Prostatic Diseases, 2021
  • Effect of COVID-19 on 18F-FDG PET/CT: Is There a Need to Consider COVID-19 Status Before Planning 18F-FDG PET/CT for Oncologic Evaluation?
    Anwin Joseph Kavanal, Santosh Ranjan Jena, Rajender Kumar, Chandan Krushna Das, Sunil Kumar, Bhagwant Rai Mittal
    Journal of Nuclear Medicine Technology, 2021
  • 'Rollover' abdominal paracentesis versus standard technique: Protocol of a crossover randomized comparative trial
    Vishal Sharma, Daya Krishna Jha, Manish Rohilla, Chandan K Das, Harjeet Singh, Santhosh Irrinki, Aashima Arora, Subhas C Saha, Pankaj Gupta, Harshal S Mandavdhare, Usha Dutta, Aman Sharma
    Future Oncology, 2021
  • Response to Concomitant Enzalutamide and 177Lu-PSMA-617 Radioligand Therapy in ATM -Mutated Metastatic Castration Resistant Prostate Cancer
    Swayamjeet Satapathy, Chandan Krushna Das, Ashwin Singh Parihar, Ashwani Sood, Bhagwant R. Mittal
    Clinical Nuclear Medicine, 2021
  • Evaluation of pulmonary infiltrate in febrile neutropenic patients of hematologic malignancies
    Ajay Gogia, ChandanK Das, Lalit Kumar, Atul Sharma, Sanjay Thulkar, Immaculata Xess, Karan Madan
    Indian Journal of Medical and Paediatric Oncology, 2021
  • Breast cancer treatment during the COVID-19 pandemic
    Atul Batra, Prashant Mehta, Amol Patel, Sainath Bhethanabhotla, Bivas Biswas, Raja Pramanik, Chandan Krushna Das
    Indian Journal of Medical and Paediatric Oncology, 2021
  • Cancer surgery in challenging time of COVID-19 pandemic-A pragmatic approach
    Shubh Mahindru, Chandan K Das, Amol Patel, Prashant Mehta, Bivas Biswas, Atul Batra, Arnab Bandhopadhyay
    Indian Journal of Medical and Paediatric Oncology, 2021
  • How i treat epithelial ovarian cancer during COVID-19 pandemic
    Chandan Krushna Das, Shubh Mahindru, Amol Patel, Atul Batra, Bivas Biswas, Prashant Mehta, Raja Pramanik, Sainath Bhethanabhotla, Vineet Govinda Gupta
    Indian Journal of Medical and Paediatric Oncology, 2021
  • Colorectal cancer chemotherapy during COVID-19 pandemic
    Sainath Bhethanabhotla, Raja Pramanik, Priyanka Srivastava, Prashant Mehta, Amol Patel, Bivas Biswas, Atul Batra, Vineet Govinda Gupta, Chandan Das, Shubh Mahindru
    Indian Journal of Medical and Paediatric Oncology, 2021
  • Management of head-and-neck cancer during COVID-19 crisis: A medical oncology perspective
    Raja Pramanik, Priyanka Srivastava, Atul Sharma, Prashant Mehta, Amol Patel, Sainath Bhethanbhotla, Bivas Biswas, Atul Batra, Vineet Govinda Gupta, Chandan Krushna Das, Shubh Mahendru
    Indian Journal of Medical and Paediatric Oncology, 2021
  • How we treat lung cancer during SARS-Cov-2 (COVID-19) pandemic in India?
    Bivas Biswas, Sandip Ganguly, Deepak Dabkara, Joydeep Ghosh, Priyanka Srivastava, Prashant Mehta, Amol Patel, Sainath Bhethanabhotla, Atul Batra, Raja Pramanik, Vineet Govinda Gupta, Chandan Krushna Das, Shubh Mahindru
    Indian Journal of Medical and Paediatric Oncology, 2021
  • Docetaxel-Induced Interstitial Pneumonitis Detected on 68Ga-PSMA PET/CT
    Sunil Kumar, Harmandeep Singh, Chandan K. Das, Rajender Kumar, Bhagwant Rai Mittal
    Clinical Nuclear Medicine, 2021
  • Locally advanced gallbladder cancer: a review of the criteria and role of imaging
    Pankaj Gupta, Kesha Meghashyam, Yashi Marodia, Vikas Gupta, Rajender Basher, Chandan Krushna Das, Thakur Deen Yadav, Santhosh Irrinki, Ritambhra Nada, Usha Dutta
    Abdominal Radiology, 2021
  • Metastatic dysgerminoma in a young patient with 46 XY DSD: A rare case report
    Surekha Thakur, S.C. Saha, Pooja Sikka, Chandan Krushna Das, Kollabathula Arpitha, Uttam Kumar Thakur
    Gynecologic Oncology Reports, 2021
  • Revisiting Fulvestrant Dosing in Uncertain Economic Times
    Amol Patel, Vineet Govinda Gupta, Bivas Biswas, Chandan K. Das, Atul Batra, Sandip Ganguly, Sainath Bhethanabhotla
    Journal of Global Oncology, 2021
  • Reply to d. o'reilly et al
    Amol Patel, Vineet Govinda Gupta, Bivas Biswas, Sandip Ganguly, Chandan K. Das, Atul Batra, Sainath Bhethanabhotla
    JCO Global Oncology, 2021
  • Computed tomography texture-based radiomics analysis in gallbladder cancer: initial experience
    Pankaj Gupta, Pratyaksha Rana, Balaji Ganeshan, Daneshwari Kalage, Santosh Irrinki, Vikas Gupta, Thakur Deen Yadav, Rajender Kumar, Chandan K. Das, Parikshaa Gupta, Raymond Endozo, Ritambhra Nada, Radhika Srinivasan, Naveen Kalra, Usha Dutta, Manavjit Sandhu
    Clinical and Experimental Hepatology, 2021
  • Diffuse large B-cell lymphoma: An institutional analysis
    Ajay Gogia, Chandan K. Das, Lalit Kumar, Atul Sharma, Akash Tiwari, M.C Sharma, Soumya Mallick
    South Asian Journal of Cancer, 2020
  • Health-related quality-of-life outcomes with actinium-225-prostate-specific membrane antigen-617 therapy in patients with heavily pretreated metastatic castration-resistant prostate cancer
    Ashwani Sood, Swayamjeet Satapathy, BhagwantRai Mittal, ChandanKrushna Das, ShrawanKumar Singh, RavimohanSuryanarayan Mavuduru, GirdharSingh Bora
    Indian Journal of Nuclear Medicine, 2020
  • Expression of CXCR4 Receptors in Refractory Atypical Mediastinal Carcinoid
    Venkata Subramanian Krishnaraju, Swayamjeet Satapathy, Ashwani Sood, Chandan Krushna Das, Debajyoti Chatterjee, Jaya Shukla, Bhagwant Rai Mittal
    Clinical Nuclear Medicine, 2020
  • 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks
    Rakhee Vatsa, Ashwani Sood, Shelvin Kumar Vadi, Chandan Krushna Das, Komalpreet Kaur, Madan Parmar, Bhagwant Rai Mittal
    Clinical Nuclear Medicine, 2020
  • Outcomes of Advanced Epithelial Ovarian Cancers Treated with Neoadjuvant Chemotherapy and Interval Debulking Surgery: An Audit from a Tertiary Care Referral Center in India
    Ankita Gupta, Divyesh Kumar, Vikrant Kaushal, Raviteja Miriyala, G. Y. Srinivasa, Treshita Dey, Bhavana Rai, Chandan K. Das, Radhika Srinivasan, Nalini Gupta, G. R. V. Prasad, Vanita Jain, Pranab Dey, Rashmi Bagga, Jaswinder Kalra, S. C. Saha, Arvind Rajwanshi, Vanita Suri, Sushmita Ghoshal
    Indian Journal of Gynecologic Oncology, 2020
  • Clinicopathological Profile of Castleman’s Disease in Indian Population: Experience From a Tertiary Care Center
    Ashok Singh, Suvendu Purkait, Saumyaranjan Mallick, Prashant Ramteke, Chandan Krushna Das, Ajay Gogia, Maher Chand Sharma, Lalit Kumar
    Indian Journal of Hematology and Blood Transfusion, 2020
  • Advisory for cancer patients during the COVIDpandemic
    Priyanka Srivastava, TV. S. V. G. K. Tilak, Amol Patel, ChandanK Das, Bivas Biswas, Shubh Mahindru, Raja Pramanik, Joydeep Ghosh, Prashant Mehta
    Cancer Research Statistics and Treatment, 2020
  • Low-dose abiraterone in metastatic prostate cancer: Is it practice changing? Facts and facets
    Amol Patel, Ian F. Tannock, Priyanka Srivastava, Bivas Biswas, Vineet Govinda Gupta, Atul Batra, Sainath Bhethanabhotla, Raja Pramanik, Shubh Mahindru, TVSVGK Tilak, Chandan Krishna Das, Prashant Mehta
    Journal of Global Oncology, 2020
  • Adenoid Cystic Carcinoma of the Vulva: Report on a Rare Malignancy
    Gargi Kapatia, Parikshaa Gupta, Rashmi Bagga, Bhavana Rai, Chandan Krushna Das, Arvind Rajwanshi
    Journal of Gynecologic Surgery, 2019
  • Multidisciplinary Surgery in a Young Woman with Endometrial Stromal Sarcoma with Inferior Vena Cava and Intracardiac Extension
    Rashmi Bagga, Pradip Kumar Saha, Ajay Savlania, Aashima Arora, Aruna Kumari, Pankaj Aggarwal, Radhika Srinivasan, Sunder Negi, Naveen Kalra, Bhavna Rai, Chandan Krushna Das
    Journal of Gynecologic Surgery, 2019
  • Cytologic diagnosis of small cell carcinoma of the ovary: A case report with review of the literature
    Parikshaa Gupta, Swathi Jogunoori, Arvind Rajwanshi, Radhika Srinivasan, Nalini Gupta, Vanita Jain, Chandan Krushna Das
    Diagnostic Cytopathology, 2019
  • Platinum sensitive carcinoma of ovary relapsed as pericardial effusion with cardiac tamponade
    Chinna Babu Dracham, Shipra Gupta, Chandan Krushna Das, Arun Elangovan
    BMJ Case Reports, 2019
  • Oncotype DX: Where does it stand in India?
    Atul Batra, Amol Patel, Vineet Govinda Gupta, Prashant Mehta, Tilak TVSVGK, Bivas Biswas, Raja Pramanik, Chandan Krishnan Das, Priyanka Srivastava
    Journal of Global Oncology, 2019
  • Profile of non-Hodgkin lymphoma: An Indian perspective
    Ajay Gogia, Chandan K. Das, Lalit Kumar, Atul Sharma, M.C Sharma, Soumya Mallick
    South Asian Journal of Cancer, 2018
  • Vinorelbine-induced chemotherapy port extravasation
    Chandan Krushna Das, Ajay Gogia
    Lancet Oncology, 2016
  • Mantle Cell Lymphoma: A North Indian Tertiary Care Centre Experience
    Chandan Krushna Das, Ajay Gogia, Lalit Kumar, Atul Sharma, Mehar Chand Sharma, et al.
    Asian Pacific Journal of Cancer Prevention, 2016
  • Mantle cell lymphoma: A North Indian tertiary care centre experience
    Asian Pacific Journal of Cancer Prevention, 2016
  • Use of induced sputum to determine the prevalence of Pneumocystis jirovecii in immunocompromised children with pneumonia
    C. K. Das, B. R. Mirdha, S. Singh, R. Seth, A. Bagga, R. Lodha, S. K. Kabra
    Journal of Tropical Pediatrics, 2014